We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...

Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) ...

When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial ...

Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...

On Friday, SpringWorks Therapeutics Inc (SWTX) stock saw a decline, ending the day at $36.45 which represents a decrease of $-0.10 or -0.27% from the prior close of $36.55. The stock opened at $36.5 ...

Shareholders of SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) will be pleased this week, given that the stock price ...

Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...